Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Esperion Therapeutics (ESPR) PT Raised to $130 at Needham & Company
May 8, 2015 7:46 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and boosted his price target on Esperion Therapeutics (NASDAQ: ESPR) to $130.00 (from $104.00), citing multiple value-creating events through year-end.
Esperion has submitted briefing documents to the FDA and expects to be able to hold... More
Esperion Therapeutics (ESPR) Misses Q1 EPS by 8c
May 7, 2015 5:02 PM EDTEsperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.56), $0.08 worse than the analyst estimate of ($0.48).
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
... More